Clinical Trial Update: Evaluation of Metionac for the Modulation of Metabolic and Endocrine Parameters in Patients With PCOS. [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Metionac for modulation of metabolic and endocrine parameters in polycystic ovary syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycystic Ovary Syndrome

Drugs mentioned

• Metionac

Snippet

Sponsor: Margan Biotech | Conditions: Polycystic Ovary Syndrome | Phase 4 | Status: COMPLETED